{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:27:19Z","timestamp":1788384439781,"version":"build-2803163510"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>There is an unmet need to develop novel treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients often develop resistance to next-generation hormonal therapies that target the androgen receptor (AR) axis (e.g., abiraterone and enzalutamide). A splice variant of AR, AR-V7, is associated with resistance to these inhibitors as well as mCRPC progression and poor prognoses. We embarked upon a high-throughput screen to identify synergistic combinations of targeted therapies using two CRPC cell lines, LNCaP95 and VCaP-CR. Combinations targeting BCL2L1 (Bcl-xL) (A-1331852 and navitoclax) and MCL1 (S63845) synergistically decreased cell viability and induced apoptotic activity via cleavage of PARP, caspase 3, and caspase 7 across AR-V7\u2013expressing CRPC cell lines (LNCaP95, VCaP-CR, and 22Rv1) and a patient-derived organoid model (LuCaP 167CR). We also explored the use of a Bcl-xL\u2013specific proteolysis-targeting chimera degrader (PROTAC) to minimize platelet toxicity associated with Bcl-xL inhibitors. We showed similar synergistic efficacy with the Bcl-xL\u2013targeting PROTAC in combination with S63845 in the three-dimensional spheroid models. Our findings support further preclinical development of Bcl-xL and Mcl-1 inhibitors for mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7\u2013expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7\u2013expressing CRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0096","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:36:38Z","timestamp":1753356998000},"page":"1396-1408","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7\u2013Expressing CRPC Models"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-3292","authenticated-orcid":false,"given":"Benjamin C.","family":"Brim","sequence":"first","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3187-6582","authenticated-orcid":false,"given":"Andres F.","family":"Leon","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4517-906X","authenticated-orcid":false,"given":"Erica L.","family":"Beatson","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-9721","authenticated-orcid":false,"given":"Jessica D.","family":"Kindrick","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0718-5078","authenticated-orcid":false,"given":"Kinjal","family":"Bhadresha","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4656","authenticated-orcid":false,"given":"Xiaohu","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7354-8693","authenticated-orcid":false,"given":"Giulia C.","family":"Napoli","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-8634","authenticated-orcid":false,"given":"Emily N.","family":"Risdon","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0285-0216","authenticated-orcid":false,"given":"Keith T.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"3Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-2766","authenticated-orcid":false,"given":"Kelli M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6554-5772","authenticated-orcid":false,"given":"Crystal","family":"McKnight","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4800-9922","authenticated-orcid":false,"given":"Erin","family":"Beck","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-6132","authenticated-orcid":false,"given":"Carleen","family":"Klumpp-Thomas","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9857-9521","authenticated-orcid":false,"given":"Michele","family":"Ceribelli","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-5463","authenticated-orcid":false,"given":"JuanJuan","family":"Yin","sequence":"additional","affiliation":[{"name":"4Prostate Cancer Genetics Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[{"name":"4Prostate Cancer Genetics Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-7510","authenticated-orcid":false,"given":"Douglas K.","family":"Price","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-3833","authenticated-orcid":false,"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":false,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2025082103214121600_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat Rev Urol"},{"key":"2025082103214121600_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"2025082103214121600_bib3","doi-asserted-by":"crossref","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"H\u00f6rnberg","year":"2011","journal-title":"PLoS One"},{"key":"2025082103214121600_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euf.2017.01.004","article-title":"Prognostic value of androgen receptor splice variant 7 in the treatment of castration-resistant prostate cancer with next generation androgen receptor signal inhibition: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2025082103214121600_bib5","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3390\/cancers14194877","article-title":"The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025082103214121600_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"2025082103214121600_bib7","doi-asserted-by":"crossref","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"key":"2025082103214121600_bib8","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/pros.23843","article-title":"Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide","volume":"79","author":"Pilling","year":"2019","journal-title":"Prostate"},{"key":"2025082103214121600_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2021.07.045","article-title":"Evasion of cell death: a contributory factor in prostate cancer development and treatment resistance","volume":"520","author":"Campbell","year":"2021","journal-title":"Cancer Lett"},{"issue":"Suppl 1","key":"2025082103214121600_bib10","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1038\/onc.2009.52","article-title":"Mimicking the BH3 domain to kill cancer cells","volume":"27","author":"Ni Chonghaile","year":"2008","journal-title":"Oncogene"},{"key":"2025082103214121600_bib11","first-page":"100756","article-title":"Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines","volume":"22","author":"Abdul Rahman","year":"2020","journal-title":"Biochem Biophys Rep"},{"key":"2025082103214121600_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41419-019-1568-3","article-title":"BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival","volume":"10","author":"Lee","year":"2019","journal-title":"Cell Death Dis"},{"key":"2025082103214121600_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41419-023-06231-y","article-title":"The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance","volume":"14","author":"Fitzgerald","year":"2023","journal-title":"Cell Death Dis"},{"key":"2025082103214121600_bib14","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","article-title":"Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis","volume":"24","author":"Arai","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025082103214121600_bib15","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025082103214121600_bib16","doi-asserted-by":"crossref","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025082103214121600_bib17","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1038\/srep13891","article-title":"High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations","volume":"5","author":"Mott","year":"2015","journal-title":"Sci Rep"},{"key":"2025082103214121600_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2025082103214121600_bib19","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3389\/fphar.2019.01384","article-title":"Additive dose response models: defining synergy","volume":"10","author":"Lederer","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025082103214121600_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/2472555217697434","article-title":"3D models of the NCI60 cell lines for screening oncology compounds","volume":"22","author":"Selby","year":"2017","journal-title":"SLAS Discov"},{"key":"2025082103214121600_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pros.23313","article-title":"LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease an\u2013d serve as models for evaluating cancer therapeutics","volume":"77","author":"Nguyen","year":"2017","journal-title":"Prostate"},{"key":"2025082103214121600_bib22","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-0409","article-title":"A PDX\/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening","volume":"24","author":"Beshiri","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025082103214121600_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2025082103214121600_bib24","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"2025082103214121600_bib25","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2025082103214121600_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2025082103214121600_bib27","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025082103214121600_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"2025082103214121600_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2018.00006","article-title":"Three-dimensional in vitro cell culture models in drug discovery and drug repositioning","volume":"9","author":"Langhans","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025082103214121600_bib30","doi-asserted-by":"crossref","first-page":"112186","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"2025082103214121600_bib31","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1039\/C9CC07217A","article-title":"Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL","volume":"55","author":"Zhang","year":"2019","journal-title":"Chem Commun (Camb)"},{"key":"2025082103214121600_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/cancers14010051","article-title":"Targeting the intrinsic apoptosis pathway: a window of opportunity for prostate cancer","volume":"14","author":"Westaby","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025082103214121600_bib33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/pros.20723","article-title":"Androgen receptor-dependent regulation of Bcl-xL expression: implication in prostate cancer progression","volume":"68","author":"Sun","year":"2008","journal-title":"Prostate"},{"key":"2025082103214121600_bib34","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3390\/ijms25116111","article-title":"Genomic characterization of preclinical prostate cancer cell line models","volume":"25","author":"Beatson","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025082103214121600_bib35","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025082103214121600_bib36","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1078-0432.CCR-18-0320","article-title":"Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY","volume":"25","author":"Tagawa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025082103214121600_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4161\/cc.6.5.3901","article-title":"A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells","volume":"6","author":"Lehmann","year":"2007","journal-title":"Cell Cycle"},{"key":"2025082103214121600_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc2402","article-title":"Recurrent gene fusions in prostate cancer","volume":"8","author":"Kumar-Sinha","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2025082103214121600_bib39","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1158\/0008-5472.CAN-09-0395","article-title":"Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer","volume":"69","author":"Cai","year":"2009","journal-title":"Cancer Res"},{"key":"2025082103214121600_bib40","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/onc.2013.284","article-title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"key":"2025082103214121600_bib41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pros.24718","article-title":"Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis","volume":"84","author":"Yin","year":"2024","journal-title":"Prostate"},{"key":"2025082103214121600_bib42","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-22-0851","article-title":"Assessment of androgen receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer","volume":"28","author":"Sowalsky","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025082103214121600_bib43","doi-asserted-by":"crossref","first-page":"118987","DOI":"10.1016\/j.bbamcr.2021.118987","article-title":"It\u2019s time to die: BH3 mimetics in solid tumors","volume":"1868","author":"Kehr","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2025082103214121600_bib44","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.oraloncology.2024.107069","article-title":"Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics","volume":"159","author":"Li","year":"2024","journal-title":"Oral Oncol"},{"key":"2025082103214121600_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025082103214121600_bib46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"2025082103214121600_bib47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2007.03.002","article-title":"A Bcl-xL timer sets platelet life span","volume":"128","author":"Qi","year":"2007","journal-title":"Cell"},{"key":"2025082103214121600_bib48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1078-0432.CCR-23-3135","article-title":"Phase I\/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors","volume":"30","author":"Corcoran","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025082103214121600_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","article-title":"Recent advances in the development of Mcl-1 inhibitors for cancer therapy","volume":"198","author":"Hird","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2025082103214121600_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.10.009","article-title":"Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy","volume":"195","author":"Yamaguchi","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2025082103214121600_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025082103214121600_bib52","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","article-title":"Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition","volume":"37","author":"Weeden","year":"2018","journal-title":"Oncogene"},{"key":"2025082103214121600_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41419-020-2646-2","article-title":"MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells","volume":"11","author":"Mukherjee","year":"2020","journal-title":"Cell Death Dis"},{"key":"2025082103214121600_bib54","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"key":"2025082103214121600_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","article-title":"Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice","volume":"9","author":"Khan","year":"2023","journal-title":"Cell Death Discov"},{"key":"2025082103214121600_bib56","doi-asserted-by":"crossref","first-page":"e179998","DOI":"10.1172\/JCI179998","article-title":"BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity","volume":"134","author":"Westaby","year":"2024","journal-title":"J Clin Invest"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0096\/3633611\/crc-25-0096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1396\/3642962\/crc-25-0096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/8\/1396\/3642962\/crc-25-0096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T07:21:55Z","timestamp":1755760915000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/8\/1396\/764232\/Direct-Co-Targeting-of-Bcl-xL-and-Mcl-1-Exhibits"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0096","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29957552","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957540","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957561","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957567","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957555","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957522","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957543","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957564","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957549","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957558","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957546","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957519","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29957528","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7992929","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}